VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

IGCS 2022 | Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary

Lilian T. Gien, MD, FRCSC, Sunnybrook Health Sciences Centre, Toronto, Canada, discusses the rationale behind evaluating combined PD-1 and IDO1 inhibition in patients with clear cell carcinoma of the ovary. This interview took place at the Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2022) in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter